Break the chain: On leprosy in India

Leprosy (Hansen's disease) is a chronic infectious disease caused by Mycobacterium leprae. It primarily affects the skin, peripheral nerves, mucosal surfaces of the upper respiratory tract, and eyes. While curable with Multi-Drug Therapy, late diagnosis often leads to irreversible nerve damage and physical deformities (Grade-2 disability). The editorial underscores the social dimension of the disease, noting that stigma remains a major barrier to seeking early care. This stigma is often rooted in fear, misunderstanding, and historical ostracization. The high incidence among children (accounting for nearly half of cases) is particularly alarming, indicating ongoing, undetected community transmission. From a UPSC perspective, this highlights the broader challenges of public health interventions where social determinants play a significant role. The uneven distribution of the disease burden, heavily concentrated in states like Chhattisgarh, Jharkhand, Odisha, and Maharashtra, points to structural inequalities in healthcare access, living conditions, and awareness, necessitating targeted, state-specific interventions rather than a uniform national approach.

The trajectory of leprosy control in India illustrates the complexities of public health governance. In 2005, following a significant drop in prevalence, the World Health Organization declared leprosy 'eliminated as a public health problem' in India (defined as less than 1 case per 10,000 population). However, as the editorial points out, this milestone led to complacency. The integration of the dedicated leprosy surveillance program into the general health system, while intended to improve efficiency, resulted in reduced active case finding. Furthermore, shortened treatment regimens meant patients were removed from registries faster, artificially lowering prevalence rates while transmission continued undetected. This scenario serves as a crucial case study for UPSC on the pitfalls of premature declaration of success in disease eradication programs and the need for sustained, active surveillance even when prevalence is low. The government's current efforts, including digital surveillance, active door-to-door screening by ASHA workers, and the administration of post-exposure prophylaxis (PEP) using single-dose rifampicin, represent a necessary course correction towards a more proactive and targeted approach. The potential use of the Mycobacterium indicus pranii vaccine (MIP vaccine) to accelerate pathogen clearance is an important technological intervention being considered.

The fight against leprosy is intrinsically linked to fundamental rights enshrined in the Constitution. The right to health, interpreted as an integral part of the Right to Life under Article 21, places an obligation on the state to provide accessible, affordable, and quality healthcare. The state's failure to adequately address the ongoing transmission and rising disability rates, despite existing frameworks like the National Leprosy Elimination Programme, can be viewed as a shortfall in fulfilling this constitutional mandate. Furthermore, the persistent stigma associated with leprosy often leads to discrimination, violating the principles of equality (Article 14) and prohibition of discrimination (Article 15). The editorial's call for the state to 'double down on interrupting transmission' and commit resources to areas where late diagnosis is prevalent aligns with the Directive Principles of State Policy, specifically Article 47, which directs the state to raise the level of nutrition and the standard of living and to improve public health. The gap between policy targets (like those in the National Strategic Plan and Roadmap for Leprosy 2023-2027) and on-ground realities, such as the shortfall in districts achieving 'interruption of transmission' and the significant overshoot in incidence projections, highlights the ongoing challenge of effective policy implementation and the need for robust accountability mechanisms within the health administration.